title: Sumatriptan provokes coronary artery spasm in patients with variant angina: possible involvement of serotonin 1B receptor.
abstract: BACKGROUND
  Serotonin (5HT) can induce coronary artery spasm (CAS) in patients with variant angina (VA). We have previously reported that 5HT(1B) and 5HT(2A) receptors gene were expressed in human coronary arterial smooth muscle cells and that isolated coronary artery from a patient with VA showed the supersensitivity to sumatriptan (SMT), a 5HT(1B/1D) receptor agonist. The aim of the present study was to determine whether SMT can provoke CAS directly or indirectly through platelet aggregation in patients with VA.
  
  
  METHODS
  We evaluated the effects of intracoronary infusion of graded concentrations of SMT on coronary arteries in 9 patients, including 5 documented VA and 4 participants with atypical chest pain as control.
  
  
  RESULTS
  SMT provoked CAS in all patients with VA. SMT could not induce CAS in control. SMT (10(-4) M) caused significant contractions (%diameter of baseline; median [interquartile range], 0 [0-18.4]% in VA, as compared with control (proximal segments; 92.6 [77.9-118.9]%, p<0.05 vs. VA, distal segments; 92.9 [65.3-158.5]%, p<0.01 vs. VA). In control, minor dilation occurred at SMT concentration up to 10(-5) M. SMT could induce in vitro platelet aggregation neither in healthy subjects nor in patients with VA.
  
  
  CONCLUSIONS
  These findings suggest that activation of 5HT(1B) receptor by SMT can induce CAS directly in patients with VA without platelet activation. This is the first report directly demonstrating the effect of 5HT(1B) receptor activation on human coronary arteries in vivo.
authors.affiliation: Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Shimizu
authors.forename: Katsuya
authors.initials: K
authors.lastname: Hata
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Takaoka
authors.forename: Kenji
authors.initials: K
authors.lastname: Kanazawa
authors.forename: Toshiro
authors.initials: T
authors.lastname: Shinke
authors.forename: Hidenari
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Satoshi
authors.initials: S
authors.lastname: Watanabe
authors.forename: Ryohei
authors.initials: R
authors.lastname: Yoshikawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Masai
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Hozuka
authors.initials: H
authors.lastname: Akita
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Yokoyama
mesh_terms: D000328:Adult; D000788:Angina Pectoris, Variant / Q000188:drug therapy*; D003329:Coronary Vasospasm / Q000139:chemically induced*; D003331:Coronary Vessels / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D044302:Receptor, Serotonin, 5-HT1B / Q000502:physiology*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D018170:Sumatriptan / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D044302:Receptor, Serotonin, 5-HT1B; D017366:Serotonin Receptor Agonists; D018170:Sumatriptan